Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 26, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details a change in the holdings of the GlaxoSmithKline US Retirement Savings Plan ("the Plan") resulting from a fund movement on January 25, 2007:
- Previous Holdings: 16,854,500 Ordinary Share ADRs
- New Holdings: 16,684,320 Ordinary Share ADRs
- Average Price: $55.75
Two directors, Dr. J P Garnier and Dr. M M Slaoui, are noted as potentially interested in the shares held in this discretionary fund, similar to other employees and former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses the notification of the share transaction in accordance with Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the impact of the reduction in ADR holdings (170,180 shares) on the total beneficial ownership of the Plan.
- Confirm the specific nature of the "movement in the fund" that triggered the change in share count.
- Review the full Disclosure Rule 3.1.4R(1)(b) requirements to ensure the notification scope is complete.